Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro (NYSE:NVRO) and Editas Medicine Inc (NASDAQ:EDIT).
Nevro (NVRO)
In a report released today, David Lewis from Morgan Stanley maintained a Hold rating on Nevro, with a price target of $65. The company’s shares closed yesterday at $58.71, close to its 52-week low of $54.87.
Lewis has an average return of 32.4% when recommending Nevro.
According to TipRanks.com, Lewis is ranked #598 out of 4843 analysts.
Nevro has an analyst consensus of Moderate Buy, with a price target consensus of $88.25, which is a 50.3% upside from current levels. In a report issued on July 10, Northland Securities also maintained a Hold rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
Editas Medicine Inc (EDIT)
In a report released today, Gbola Amusa from Chardan Capital assigned a Buy rating to Editas Medicine Inc. The company’s shares closed yesterday at $35.20.
Amusa noted:
“We note, the data here are not specific to CRISPR. The large deletions can occur due to a process known as “end resection” that takes place in multiple cell types in preparation for homology-directed repair. While this study employs CRISPR, it does not mean other nucleases (TALENs, ZFNs, meganucleases) would not pose a similar risk. That said, as we have previously noted, any gene therapy requires an evaluation of its relative risks and benefits. In its recent draft guidance, the FDA has provided recommendations for monitoring patients receiving gene editing based therapies, without the assumption of no off-target editing. We expect these data may prompt the FDA to require the inclusion of some additional safety analyses for preclinical or clinical studies, but do not expect this development to preclude the progress of gene editing therapies in the clinic.”
According to TipRanks.com, Amusa is a top 100 analyst with an average return of 30.3% and a 56.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine Inc with a $39 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
